Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, today celebrates World Blood Donor Day. The annual event serves to raise awareness of the importance of donating blood and the need for safe blood and blood products. The day is also an opportunity to thank all blood donors across the world.
For 2022, the World Blood Donor Day slogan is “Give blood and keep the world beating”, to highlight the essential contribution that blood donors provide by saving lives and improving other’s health.
To recognise the critical role of donors, BPL thanks its own donors who give plasma at BPL’s 29 collection centres in the US. The people who walk into these centres are much more than donors – they are lifelines. Their donation transforms the lives of patients around the world and BPL is deeply grateful to each and every one of them.
BPL Plasma, which has been a global leader in the plasma collection industry for more than 25 years, employs over 900 staff to support the needs of donors and ensure high-quality plasma collection in all of their centres. This plasma is collected and processed to manufacture BPL’s plasma-derived therapies.
As part of its commitment to quality and education, BPL will be presenting next month at the International Society on Thrombosis and Haemostasis (ISTH) Congress in London (9-13 July). The event brings together thousands of the world’s leading experts in the field of thrombosis, haemostasis and vascular biology to present the most recent advances, exchange the latest science and discuss the newest clinical applications designed to improve patient care.
At the Congress, BPL will be providing a scientific presentation on rare bleeding disorder therapies during a product theatre targeted at healthcare professionals.
Bob Rossilli, Chief Commercial Officer, Global Business, commented, “As organisations and communities around the world celebrate World Blood Donor Day, we wish to give thanks to our plasma donors and acknowledge their vital contribution to the plasma industry and those patients in need of plasma-derived therapies.
As part of our ongoing commitment to our patients, we are delighted to be presenting at the ISTH Congress next month. With over 8,000 global participants, we are looking forward to sharing our plasma biologics expertise to a broad audience which includes other leading industry experts.”
Donna Mitchell, BPL Communications Manager
About Bio Products Laboratory (BPL)
Recognising the importance of plasma and with many years of experience in the industry, BPL supplies high-quality plasma derived medicines to meet the needs of clinicians, patients, and customers globally. Headquartered in the United Kingdom, with US offices in Durham, NC, and plasma collection centres across the United States, we are dedicated to producing medicines for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well for critical care. BPL invests in the latest R&D, technology and manufacturing methods, and continuously adapts to ensure that we continue to serve all our stakeholders effectively. For more information visit http://www.bplgroup.com or https://www.bpl-us.com.
BPL consists of two operating divisions — BPL Plasma and BPL Therapeutics. BPL Plasma, headquartered in Austin, Texas and operating in the USA, collects plasma from donors in around 28 centers across the U.S. BPL Plasma employs over 900 staff to support the needs of donors and to ensure high-quality plasma collection in all their centers. Plasma collection is regulated by both FDA and MHRA, and BPL Plasma follows industry guidelines. BPL Plasma operates plasma facilities, staffed with trained personnel, dedicated to supporting donors through the process that leads to the donation of plasma. Plasma is shipped to the headquarters of BPL Therapeutics in Elstree, United Kingdom. The plasma is fractionated, purified, and filled through the efforts of our over 1,000 employees involved in production, quality, R&D, commercial, customer services, and administrative activities. BPL’s plasma-derived medicines are commercially available in the U.K., USA, and 30 plus other countries around the world through our network of local affiliates and distribution partners.